La Jolla Pharmaceutical (LJPC) Expected to Post Earnings of -$1.12 Per Share
Equities analysts forecast that La Jolla Pharmaceutical (NASDAQ:LJPC) will announce earnings per share of ($1.12) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for La Jolla Pharmaceutical’s earnings. The highest EPS estimate is ($1.09) and the lowest is ($1.17). La Jolla Pharmaceutical posted earnings of ($2.02) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 44.6%. The business is expected to announce its next quarterly earnings report on Wednesday, August 14th.
On average, analysts expect that La Jolla Pharmaceutical will report full year earnings of ($4.43) per share for the current fiscal year, with EPS estimates ranging from ($4.70) to ($4.18). For the next fiscal year, analysts forecast that the firm will post earnings of ($2.55) per share, with EPS estimates ranging from ($3.25) to ($1.45). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for La Jolla Pharmaceutical.
La Jolla Pharmaceutical (NASDAQ:LJPC) last announced its quarterly earnings data on Monday, May 6th. The biopharmaceutical company reported ($1.17) EPS for the quarter, beating the consensus estimate of ($1.31) by $0.14. La Jolla Pharmaceutical had a negative return on equity of 337.55% and a negative net margin of 1,324.04%. The firm had revenue of $4.40 million for the quarter, compared to analyst estimates of $4.98 million.
LJPC traded up $0.03 on Tuesday, hitting $5.82. 291,131 shares of the company were exchanged, compared to its average volume of 831,522. La Jolla Pharmaceutical has a 12 month low of $5.01 and a 12 month high of $38.39. The firm has a market cap of $157.72 million, a price-to-earnings ratio of -0.74 and a beta of 1.41.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Tang Capital Management LLC grew its position in La Jolla Pharmaceutical by 27.3% during the 1st quarter. Tang Capital Management LLC now owns 4,938,893 shares of the biopharmaceutical company’s stock worth $31,757,000 after acquiring an additional 1,060,000 shares during the last quarter. FMR LLC lifted its stake in shares of La Jolla Pharmaceutical by 3.3% in the 1st quarter. FMR LLC now owns 4,061,425 shares of the biopharmaceutical company’s stock valued at $26,115,000 after purchasing an additional 128,074 shares during the period. Broadfin Capital LLC lifted its stake in shares of La Jolla Pharmaceutical by 2.4% in the 1st quarter. Broadfin Capital LLC now owns 1,994,911 shares of the biopharmaceutical company’s stock valued at $12,827,000 after purchasing an additional 47,370 shares during the period. Sectoral Asset Management Inc lifted its stake in shares of La Jolla Pharmaceutical by 6.7% in the 4th quarter. Sectoral Asset Management Inc now owns 1,759,171 shares of the biopharmaceutical company’s stock valued at $16,589,000 after purchasing an additional 110,399 shares during the period. Finally, BlackRock Inc. lifted its stake in shares of La Jolla Pharmaceutical by 1.3% in the 4th quarter. BlackRock Inc. now owns 1,498,561 shares of the biopharmaceutical company’s stock valued at $14,132,000 after purchasing an additional 18,557 shares during the period.
About La Jolla Pharmaceutical
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock.
Featured Article: What strategies should day traders use to execute a trade?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.